1. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), and Center for Biologics Evaluation and Research (CBER). Patient-focused drug development: methods to identify what is important to patients guidance for industry, Food and Drug Administration Staff, and Other Stakeholders—DRAFT guidance. October 2019, US Department of Health and Human Services FDA: Silver Spring, MD. p. 1–45.
2. Food and Drug Administration (FDA). Patient-focused drug development guidance public workshop—incorporating clinical outcome assessments into endpoints for regulatory decision-making. Workshop Date: December 6, 2019: Silver Spring, MD. p. 1–50.
3. Food and Drug Administration (FDA). Patient-focused drug development guidance public workshop—methods to identify what is important to patients and select, develop or modify fit-for-purpose clinical outcomes assessments. Workshop Date: October 15–16, 2018: Silver Spring, MD. p. 1–57.
4. Anthony L, et al. Understanding the patient experience with carcinoid syndrome: exit interviews from a randomized, placebo-controlled study of telotristat ethyl. Clin Ther. 2017;39(11):2158–68.
5. Ervin C, et al. Insights into patients’ experience with type 1 diabetes: exit interviews from phase III studies of sotagliflozin. Clin Ther. 2019;41(11):2219-2230 e6.